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ABSTRACT
The cancer stem cell (CSC) concept suggests that neoplastic clones are maintained
exclusively by a rare group of cells possessed with stem cell properties. CSCs are
characterized by features that include self-renewal, pluripotency and tumorigenicity, and
are thought to be solely responsible for tumor recurrence and metastasis. A hierarchically
organized CSC model is becoming increasingly evident for various types of cancer,
including prostate cancer. The CD44 (+), CD133 (+) cell subpopulations were isolated
from human prostate tumors which exhibit stem-like properties showing therapeuticresistance, capacity of self-renewal, and exact recapitulation of the original tumor in
vivo. Thus, an important challenge is to find measures to eliminate these cancer stem
cells, which will stop tumor growth and prevent disease-recurrence. However, knowledge
about molecular features critical for the survival of prostate cancer stem cells (PCSC) is
meager. Here we report that inhibition of 5-lipoxygenase (5-Lox) by shRNA or MK591
dramatically kills PCSC by inducing apoptosis, suggesting that 5-Lox plays an essential
role in the survival of PCSC. Interestingly, MK591 treatment decreases protein levels
and inhibits transcriptional activities of Nanog and c-Myc. Since Nanog and c-Myc play
important roles as stemness factors, our findings indicate that the 5-Lox activity plays a
causal role in maintaining prostate cancer stemness via regulation of Nanog and c-Myc,
and suggest that further exploration of 5-Lox-mediated signaling in PCSC may lead to
development of novel, target-based, durable strategies to effectively block development
and growth of prostate tumors, and prevent prostate cancer recurrence.

INTRODUCTION

with stemness. Though our knowledge of CSCs and their
micro-environmental niche is still a relatively new field,
recent understanding about CSC’s dependence on critical
survival and self-renewal signaling makes these regulatory
pathways ready for development of novel therapeutic
strategies. Cancer stem cells are a rare subset of cells
in a tumor which are capable of eluding conventional
treatment regimen and eventually regenerate tumors.
Cancer stem cells can be extracted from a tumor based on
molecular markers, and transplanted to form new tumors,
from which the same tumor-propagating cells can again
be isolated and re-transplanted [8]. This view puts forth
the hypothesis that the vast majority of cells in a tumor
undergo differentiation after originating from cancer
stem cell and lose their self-renewal potential, and thus,
cannot contribute to tumor formation and perpetuation.

The concept of cancer stem cell propounds that
a small fraction of cells in tumors are capable of selfrenewal and to differentiate into various types of tumor
cells, and are responsible for tumor formation, growth,
progression and recurrence, while the majority of cells
that make up bulk of the tumors are non-tumorigenic
end cells [1–3]. The discovery of cancer stem cells has
redesigned the concept of therapy of various types of
cancer, because the “non-stem” cancer cells in a tumor
can be destroyed by conventional therapies (e.g., radiation,
surgery, chemotherapy), but these approaches are rarely
successful in eliminating cancer stem cells [4–7]. Thus,
the goal of current cancer therapy should be to develop
strategies to destroy these resistant cancer cells endowed
www.oncotarget.com
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The cancer stem cell concept has inspired many due to the
potential of providing more durable and broadly applicable
cancer cures by locating and targeting the tumor’s most
notorious cells. However, many of the molecular features
that regulate stemness and survival of cancer stem cells
for their seemingly infinite and incessant proliferative
capabilities are just now beginning to be appreciated.
Cancer cells with stem-like properties have been
identified in prostate tumors and characterized to be
the population responsible for generating the diverse
cell types within prostate tumors [8–12]. CSCs are also
regarded as the seeds for therapeutic resistance, tumor
recurrence and metastasis, and are recognized by a number
of defined markers, such as they are positive for CD133
and CD44, and express high levels of integrin alpha2beta1
[13–17]. Recent identification of pluripotency markers
(Nanog, c-Myc, Sox2) in prostate cancer stem cells and
characterization of their unique molecular properties have
opened up possibilities about how they can be targeted for
more effective therapies. However, many of the stemness
as well as tumorigenic markers are also present in other
body cells, including normal stem cells [18, 19]. Thus,
finding the root cause of therapeutic failures and targetable
unique molecular properties need further characterization
of prostate cancer stem cells. Most current therapies
are directed to the majority of tumor mass consisting of
fast-growing, differentiated cells but not the relatively
slow-growing and resistant cancer stem cells which
may underlie as a mechanism of why the cancer is not
permanently eradicated with standard chemotherapy. The
concept of CSC claims that cancers are driven by a set of
stem cells in the same way as adult organs are maintained
by dedicated tissue-specific stem cells [18]. Provoked by
this new concept, a lot of excitement is now directed to
go right after the root cause of the tumor and target those
stem cells and eradicate cancer permanently. However, the
destruction of prostate cancer stem cells should include
measures that will selectively and systematically affect
functions of critical molecular markers responsible for
the maintenance, growth and differentiation of PCSCs.
Thus, our approach was directed to examine the role of
a newly-characterized mechanism, which plays important
roles in the survival and proliferation of prostate cancer
cells but not of normal cells [20–26], in the maintenance
of stemness and survival of PCSC.
Our strategy was to utilize an established, clinicallyrelevant model of human PCSCs to interrogate the
mechanisms of stem cell vulnerabilities and to find
effective measures for controlling the population of PCSC
which express both pluripotency markers (Nanog, c-Myc
and Sox2) as well as the tumor-progenitor markers (CD44,
CD133, and ALDH1) [27–29]. Especially for this work,
our goal was to explore and characterize the role of a
fatty acid metabolic pathway in human prostate tumorderived stem cells, to see whether it could be used as a
mechanism-based target to control PCSC. Interestingly,
www.oncotarget.com

most non-cancer parenchyma body cells, including
normal stem cells, do not express 5-Lox under normal
conditions, presumably because of hyper-methylation of
the 5-Lox promoter [30, 31]. Moreover, 5-Lox knock-out
mice have been developed which grow normally without
any abnormalities and are fertile with normal litter size,
supporting the concept that targeting 5-Lox may turnout to be a viable strategy to effectively eliminate PCSC
without affecting most other normal body cells, and thus
will not trigger overt toxicity to general health. We found
that inhibition of 5-Lox downregulates Nanog, c-Myc and
Sox2 and blocks sphere-formation, which suggests that
the stemness characteristics in these cells are vulnerable to
inhibition of 5-Lox activity. We also found that MK591, a
specific 5-Lox inhibitor, dramatically reduces the viability
and colony-forming abilities of PCSC, and induces c-JNKdependent apoptosis. These findings indicate that 5-Lox
activity plays an important role in the survival of PCSC,
and suggest that an effective, long-term curative therapy of
prostate cancer is possible by targeting 5-Lox with suitable
agents to eliminate PCSC via induction of apoptosis.

RESULTS
Flow chart for isolation and characterization of
prostate cancer stem cells from patient-derived
tumors
A flow chart depicting the process of isolation of
prostate cancer stem cells from patient prostate tumors
is shown in Figure 1. These cells were rigorously tested
for expression of stemness markers as well as for their
high tumorigenicity by injecting 1000 cells per injection
site in SCID (Severe Combined Immuno-Deficient) mice
for quality control (Courtesy: Dr. Jay Sharma, Celprogen.
com, Torrance, CA). These cells were cultured on
ECM (E36103-3PD)-coated plates in complete growth
medium (M36103-30S) and incubated at 37°C in the
incubator for expansion to get the desired numbers of
cells for experiments. Positive markers for stemness
and tumorigenicity of these cells were extensively
characterized as a part of this study (Please see below).

5-lipoxygenase is heavily expressed in prostate
cancer stem cells and plays a critical role in their
survival
Earlier we reported that under standard culture
condition prostate cancer cells express 5-Lox but noncancer cells do not, and that the 5-Lox activity plays a
critical role in the survival of prostate cancer cells [20–26].
However, nothing was known about whether 5-Lox plays
any role in the survival of prostate cancer stem cells. To
explore a possible role of 5-Lox in prostate cancer stem
cells, we observed that treatment with MK591, which
specifically inhibits 5-Lox activity by binding with FLAP
425
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or 5-lipoxygenase-activating protein [32–36], dramatically
decreases the viability of PCSCs in a clear dose- and timedependent manner (Figure 2A–2E). Similar changes were
also found when PCSCs were treated with 5-Lox shRNA,
confirming a role of 5-Lox in the viability of these cells
(Figure 2F–2H). Interestingly, MK591 does not affect the
viability of normal cells or non-cancer stem cells under
similar experimental conditions. To understand the basis
of this differential sensitivity to 5-Lox inhibitors, we
found that in contrast to prostate cancer stem cells, normal
fibroblasts or the non-cancer stem cells do not express
5-Lox. These findings suggest that specific inhibitors
of 5-Lox may turn out to be useful to specifically target
PCSCs without harming non-cancer body cells. Though
we are intrigued by this novel and unexpected observation,
downstream signaling mechanisms which mediate the
regulation of prostate cancer stem cell survival by 5-Lox
activity are yet to be fully understood.

that the 5-Lox activity plays an important role in the
regulation of stemness in PCSCs (Figure 3A). The
decrease in protein level of Nanog was also found to
be well-correlated with a decrease in its transcriptional
activity (Figure 3B). Recently, we reported that inhibition
of 5-Lox downregulates expression and function of
c-Myc in prostate cancer cells involving inhibition of
Stat3-mediated transcription [25, 26]. Moreover, we
observed that inhibition of 5-Lox downregulates CD44,
CD133, ALDH1 and ABCG2 which are characterized to
be cancer stem cell- or tumorigenicity-markers in adult
stem cells (Figure 3C). Though mechanistic details of
the regulation of stemness factors by the activity of
5-Lox in the biology of PCSC are yet to be understood,
our findings show a possible molecular connection
between metabolism of arachidonic acid through 5-Lox
and the maintenance of stemness in prostate cancer stem
cells. Formation of spheres in low-attachment plates is a
standard characteristic of cancer stemness. Interestingly,
we found that MK591 treatment dramatically inhibits the
sphere-forming ability of PCSCs in a clear dose-dependent
manner, suggesting that the 5-Lox activity is critical for
maintaining stemness in these cells (Figure 3D).

Inhibition of 5-Lox downregulates stemness in
prostate cancer stem cells
Stemness in normal as well as cancer stem cells
is maintained by a list of transcription factors such as,
Nanog, c-Myc, Oct-4 and Sox-2 [13–17]. These stemness
factors have also been well-characterized in PCSC
and found to play important roles in the maintenance
of stemness. However, details of their upstream and
downstream regulations have yet to be fully characterized
which may yield valuable information about manipulating
them for long-term cancer control. Interestingly, we found
that inhibition of 5-Lox dramatically downregulates the
protein levels of Nanog, c-Myc and Sox2, indicating

MK591 destabilizes mitochondria and induces
apoptosis in prostate cancer stem cells
Based on previous observations of a critical role of
5-Lox activity in prostate cancer stem cell survival, we
wanted to explore downstream signaling mechanism(s)
regulated by 5-Lox using MK591, a specific inhibitor
of 5-Lox activity. We found that MK591 dramatically
induces mitochondrial-membrane depolarization, which

Figure 1: Flow chart of isolation and characterization of prostate cancer stem cells from human tumors. Human prostate

tumor tissues were finely minced with scalpel and placed on ECM (E36103-3PD)-coated plates in complete growth medium (M36103-30S)
and incubated at 37°C in the incubator for seven days. Then the tissues were lysed in protease enzyme solution to make single cell suspension
and sorted by Flow Cytometry using indicated markers. Positive cells were cultured in non-differentiating complete growth medium for
expansion of cells and finally tested for tumorigenicity using 1000 cells per injection site in SCID mice to develop subcutaneous tumors
in ten days.
www.oncotarget.com
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is indicated by the loss of permeability barrier of
mitotracker-red (Figure 4A, 4B). Externalization of
phosphatidylserine is a hall-mark of apoptotic cell death.
Thus, we wanted to examine whether prostate cancer stem
cells also externalize phosphatidylserine when treated
with MK591. We observed that prostate cancer stem
cells show distinctly positive binding with annexin-V
when treated with MK591, indicating externalization of
phosphatidylserine to the cell surface (Figure 4C). We also
observed that when prostate cancer stem cells were treated
with MK591, these cells showed severe morphological
alteration in a time-dependent manner. Characteristic
caspase-mediated cleavage of poly-ADP-ribose
polymerase (PARP) is another indicator of apoptosis,

which was also observed in PCSC when treated with
MK591 (Figure 4D), suggesting that inhibition of 5-Lox
kills prostate cancer stem cells by triggering apoptosis.

Inhibition of 5-Lox triggers apoptosis in
prostate cancer stem cells via activation of c-Jun
N-terminal kinase
Previously we have addressed the mechanism
behind 5-Lox inhibition-induced apoptosis-triggering
in prostate cancer cells, which revealed the involvement
of c-Jun N-terminal Kinase and caspase-3 [22]. To
explore the underlying mechanism in 5-Lox inhibitioninduced apoptosis in PCSC, we found that inhibition

Figure 2: MK591 decreases viability of prostate cancer stem cells, but not of non-cancer cells or normal stem cells.

(A), Human tumor-derived primary prostate cancer stem cells (Pri-PCSC) and DU145 cell line-derived cancer stem cells (DU-PCSC) were
plated in 96 well tissue culture plates in complete growth medium supplemented with 10% serum. Normal human foreskin fibroblasts
(HFF) and cord blood stem cells (CBSC) were also plated in serum-supplemented complete growth medium in parallel, Then, the cells were
treated with varying doses of MK591, and the plates were further incubated for 72 hours at 37°C in the CO2 incubator. After incubation, cell
viability was measured by MTS assay (Promega Corp, Wisconsin, MD). In (B), protein level of 5-lox was detected by Western blot. (C)
and (D) show morphological alterations and culture density of normal HFF cells and PCSC as detected by microscopy. In (E) sensitivity of
prostate cancer stem cells to different compounds was tested by MTS assay. Data presented as mean values of quadruplicate determination
of each data point ± Standard Error. Note: While MK591 effectively killed PCSC, ibuprofen (a cyclooxygenase inhibitor) and cisplatin
were found ineffective. (F–H) show morphology, level of 5-Lox protein, and viability of PCSC after treatment with shRNA against 5-Lox.
www.oncotarget.com
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of 5-Lox triggers rapid and robust activation of c-Jun
N-terminal kinase in a dose- and time-dependent manner
(Figure 5A, 5B). Further analysis revealed that the MK591
treatment-induced apoptosis in PCSC is inhibited when
the cells were pretreated with an inhibitor of c-JNK
(SP600125), suggesting that 5-Lox inhibition-induced
apoptosis in PCSCs is dependent on c-JNK activity
(Figure 5C). Interestingly, cells treated with ibuprofen
(a cyclooxygenase inhibitor) did not show any signs of
apoptosis, suggesting specific effects of 5-Lox inhibition
to induce apoptosis in prostate cancer stem cells.

the effect of 5-Lox inhibition on well-characterized
survival-regulating kinases. Previously, we reported
that inhibition of 5-Lox induces apoptosis in prostate
cancer cells without inhibition of the Akt, or ERK, but
via a rapid decrease in the membrane-localization as well
as enzymatic activity of PKCε [23, 37]. Involvement
of PKCε has been reported to promote survival and
decrease apoptosis in a variety of other cells [38–40].
To explore the kinase responsible for this mechanism of
cell death in PCSC, we observed that inhibition of 5-Lox
downregulates PKCε and phosphorylation of its substrates,
but does not affect Akt or ERK in the same experimental
conditions, suggesting that PKCε mediates the survivalregulating effects of 5-Lox in PCSCs (Figure 6A). We also
observed that inhibition of 5-Lox decreases the proteinlevels of survivin, cyclin D1, CDK4 and Bcl-xl, which are
well-known regulators of cell survival and proliferation
(Figure 6B).

Inhibition of 5-Lox induces apoptosis in prostate
cancer stem cells via downregulation of PKCε,
but without inhibition of Akt or ERK
How inhibition of 5-Lox triggers apoptosis in PCSC
is an intriguing question. We addressed this by examining

Figure 3: Inhibition of 5-Lox downregulates stemness in PCSC. In (A), PCSCs (3 × 105 per plate) were plated in complete

growth medium supplemented with 10% serum in 60 mm diameter plates and allowed to grow for 48 hours. On the day of experiment,
the spent culture medium was replaced with 2 ml fresh RPMI medium and the cells were treated with MK591 or ibuprofen at 37°C for 24
hours as indicated. Control cells were treated with solvent only (0.2% DMSO). At the end of incubation period, cells were harvested and
lysed. Protein levels in treated and untreated cells were detected by Western blot. (B) shows transcriptional activity of Nanog after treatment
with varying doses of MK591 in Nanog-luciferase transfected PCSC. In (C), protein levels of adult stem cell markers are shown with or
without treatment with MK591. (D) shows effect of MK591 on sphere formation by PCSC in ultra-low attachment plates in complete
growth medium.
www.oncotarget.com
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DISCUSSION

Inhibition of 5-Lox blocks in vitro invasion as
well as soft-agar colony formation by prostate
cancer stem cells

Our findings, for the first time, document that 5-Lox
plays an essential role in the survival of prostate cancer
stem cells, and that inhibition of 5-Lox kills these cells via
induction of c-JNK-mediated apoptosis. Our observation
of the massive induction of apoptosis in prostate cancer
stem cells by specific inhibition of 5-Lox, opened
up a unique possibility that both the progression and
recurrence of prostate tumors can be vertically checked
by eliminating these self-perpetuating and pluripotent
cells by specific inhibitors of 5-Lox, such as MK591
(Figures 1, 2). We found that the prostate cancer stem
cell subpopulation overexpress stem cells markers such
as Nanog, c-Myc and Sox2 which play important roles
in cancer stemness signaling. Interestingly, protein levels
of these factors and sphere-forming abilities of PCSCs
are severely down-regulated when the cells are treated
with 5-Lox inhibitors (Figure 3), which suggest that the
expression and function of the stemness factors in prostate

We observed that treatment with sub-lethal doses
of MK591 (10–20 μM) dramatically decrease the in vitro
invasion of prostate cancer stem cells through extracellular
matrix (Figure 7A, 7B). Moreover, we found that MK591
dramatically affects the anchorage-independent colonyforming ability of prostate cancer stem cells on soft-agar
(Figure 7C, 7D). Note: Ibuprofen and cisplatin were
used in parallel experiments and found to be ineffective
to block colony formation by prostate cancer stem cells
in the same culture conditions, suggesting that the effect
of 5-Lox inhibition in these processes is highly selective.
These in vitro experiments indicate that the activity of
5-Lox is important for the maintenance of stemness and
survival of PCSCs, and suggest that it is possible to inhibit
the tumor-forming ability and therapeutic-resistance of
PCSC by targeting 5-Lox with suitable agents (Figure 8).

Figure 4: Inhibition of 5-Lox triggers mitochondrial permeability transition and induces apoptosis in PCSCs. In (A) and

(B), PCSC and DU-PCSC (3 × 105 per plate) were plated in complete growth medium supplemented with 10% serum in 60 mm diameter
plates and allowed to grow for 48 hours. On the day of experiment, the spent culture medium was replaced with 2 ml fresh RPMI medium
and the cells were treated with MK591 as described in Figure 2. Then the cells were treated either with MK591 (30 μM) or ibuprofen
(30 μM) for 24 hours. Then, the cells were stained with mitotracker-red for 60 minutes, counter-stained with Hoechst 33342 dye (blue), and
observed under a fluorescent microscope (C). Membrane lipid asymmetry was detected by Annexin V binding. At the end of incubation
period, cells in binding buffer were treated with FITC-labeled annexin-V and propidium iodide, and were observed under microscope at
20×. In (D), at the end of incubation, cells were lysed and cleavage of PARP was detected by Western blot.

www.oncotarget.com
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cancer stem cells are dependent on 5-Lox activity. An
important role of Myc has been characterized in cancer
stem cells, and the formation of spheres in low-attachment
plates is a confirmative test for cancer-stemness [41–44].
Moreover, loss of 5-Lox activity triggers mitochondrial
permeability-transition and induces apoptosis in these cells
(Figure 4). It has been characterized that CSCs are highly
prolific and considerably more resistant to conventional
chemotherapeutics (such as, cisplatin, paclitaxel,
adriamycin, and methotrexate) and radiation, meaning
while common therapeutic procedures eliminate majority
of actively proliferating cancer cells and yield bulk tumor
shrinkage, the population of CSC survive because of
their relatively slow growth and aberrant activation of
signaling pathways. However, we observed that inhibition
of 5-Lox commits these cells to undergo self-killing via
phosphatidylserine externalization, and cleavage of PARP
protein. Moreover, we observed that 5-Lox inhibitioninduced apoptosis in PCSC is mediated via activation of
c-Jun N-terminal Kinase (Figure 5). Thus, we hope that

agents such as MK591 may constitute valuable tools to
exhaust the options of survival of these stubborn cells with
virtually infinite self-renewing and incessant proliferating
capabilities.
Though the 5-Lox activity appears to play an
important role in the survival of PCSC, downstream
mechanism through which 5-Lox delivers survival
signaling is not clearly understood. We found that
inhibition of 5-Lox triggers apoptosis in PCSC without
inhibition of PI3K-Akt, or MEK-ERK, two wellcharacterized pro-survival mechanisms, but dramatically
decreases the protein level of protein kinase C-epsilon
(PKCε). These findings suggest that downstream
mechanisms which mediate the survival-promoting effects
of 5-Lox metabolites in PCSC involve the activity of
PKCε, but not the more prevalent Akt or ERKs (Figure 6).
Cancer stem cells possess the ability to disseminate and
adhere to distant sites while retaining their stemness
characteristics and thus regrow the tumor mass at new sites
which eventually gives rise to metastatic lesions eventually

Figure 5: MK591 treatment triggers activation of c-Jun N-terminal Kinase which plays a critical role in apoptosis. PCSCs

(3 × 105 per plate) were plated in complete growth medium supplemented with 10% serum in 60 mm diameter plates and allowed to grow for 48
hours. On the day of experiment, the spent culture medium was replaced with 2 ml fresh RPMI medium and the cells were treated with MK591
as described in Figure 2 for 24 hours. In (A and B), dose and time-dependent changes in phosphorylation of c-JNK by MK591 treatment
were detected by Western blots using phospho-specific antibodies. In (C), cells were pre-treated with c-JNK inhibitor (SP = SP600125) for
30 minutes before treatment with MK591, and cell death was detected by staining with Annexin V-FITC as in Figure 4 above.
www.oncotarget.com
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causing demise of the affected patients. Though CSCs
constitute only a minor population in a tumor, they are
extremely potent to generate the heterogeneous lineages
of cancer cells that make up bulk of the tumor, signifying
the importance of identifying robust agents which can
broadly affect and eliminate the metastatic ability of CSC.
Interestingly, we found that MK591 strongly inhibits the
in vitro invasion and completely blocks the anchorageindependent colony forming abilities of PCSCs on softagar at sub-lethal doses (Figure 7). Previously we have
demonstrated that in standard culture condition human
prostate cancer cells continuously generate metabolites
of 5-Lox from arachidonic acid which play an essential
role in their survival [23–26]. Blocking 5-Lox activity
triggers rapid apoptosis in prostate cancer cells which can
be effectively prevented by exogenous active metabolites
of 5-Lox, 5(S)-HETE and its dehydrogenated derivative
5-oxoETE, documenting a pro-survival role of these
metabolites in prostate cancer cells. The findings from
our current in vitro experiments indicate that inhibition of
5-Lox triggers apoptosis also in prostate cancer stem cells,
suggesting that 5-Lox activity greatly contributes to the
survival and apoptosis-resistance of prostate cancer stem
cells by metabolic conversion of arachidonic acid, and
signaling via a mechanism which is similar to that what
exists also in differentiated prostate cancer cells.
CSCs are a rare sub-population of cells present
within the tumor, and are responsible for tumor-initiation,
maintenance and tumor-recurrence. They possess
unique biological properties, such as self-renewal and
pluripotency. Moreover, they are thought to be more
resistant to conventional chemotherapy and, as a result,
are responsible for disease relapse. The core principle of

cancer stem cells suggests that somewhere at the heart
of a tumor there lies a handful of aberrant, genetically
altered cells that are critical to maintain the malignant
characteristics. This idea bears the potential to explain
why tumors often regenerate long-time after even being
destroyed by standard anticancer regimen. Moreover,
it points to an alternative strategy for developing new
generation of anticancer drugs, suggesting that these
agents should be more selective towards the lethality of
cancer stem cells and not to kill just any cells to shrink the
tumor mass. Interestingly, cancer stem cells share many
characteristics with normal stem cells, which include selfperpetuation and differentiation to other cells, and with
growing evidence that cancer stem cells indeed exist in a
wide variety of tumor types, it is changing the landscape of
tumor biology research. It is also becoming increasingly
relevant to understand the basic molecular mechanisms
that regulate their self-renewal and differentiation because
deregulation of genes involved in these pathways likely
participate in basic characteristics of cancer viz tumor
growth, recurrence and metastatic spread. The important
question now is how to eliminate the cancer stem cells
without killing normal stem cells because they are vital
for maintaining tissue homeostasis? Since the inexorable
growth of tumor is maintained by this rare group of stem/
progenitor cells within it, we can expect that the cancer
stem cells, because of their unique biological features,
may be more dependent on certain cellular processes than
normal cells and thus, will be more vulnerable to some
agents that block those processes. However, sorting out
unique pathways that are critical for cancer stem cells, but
not for non-tumor cells, though of utmost importance, is
incredibly complex.

Figure 6: 5-Lox inhibition-induced apoptosis in prostate cancer stem cells involves inhibition of PKCε, but not Akt or
ERK. PCS cells (3 × 105 per plate) were plated in complete growth medium supplemented with 10% serum in 60 mm diameter plates and
allowed to grow for 48 hours. On the day of experiment, the spent culture medium was replaced with 2 ml fresh RPMI medium and the cells
were treated either with MK591 (10–30 μM) or ibuprofen (30 μM) for 24 hours. Control cells were treated with vehicle only (0.2% DMSO).
At the end of incubation, cells were harvested and proteins were separated in 12% SDS-PAGE. In (A), protein levels of PKC-epsilon and
phosphorylations of Akt-pSer473, ERK-pThr202/Y204, Nanog-pThr200 and Stat3-pSer727, and in (B) protein levels of survivin, cyclin D1, CDK4
and Bcl-xl were detected by Western blot. Data show a representative of three independent experiments with similar results.
www.oncotarget.com
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Figure 7: Effects of MK591 on in vitro invasion and soft-agar colony formation by PCSC. In (A), invasive capabilities of

PCS cells were assayed using matrigel-coated transwell chambers as described in the “Methods” section. After incubation, cells were fixed
and stained with crystal violet. Pictures were taken with a Leica microscope at ×200. (B) Shows quantitative measurements of the number
of invaded cells with or without drug treatment. Results represent mean values of individual data point ± standard deviation (n = 3). ****p = <
0.00005; *****p = < 0.000005. In (C), effects of MK591 on soft-agar colony formation by PCSC are shown. Cells were plated on soft-agar in
complete medium and treated with drugs as indicated. After incubation for three weeks, cells were stained with crystal-violet and growing
colonies were counted under microscope at ×150. Note: Dramatic inhibition was observed with MK591 treatment whereas the effects of
ibuprofen and cisplatin were not distinguishable. In (D), results are shown quantitatively as mean values of each data point ± standard
deviation (n = 3). ****p = < 0.00005.

Figure 8: Diagrammatic representation of the role of 5-lipoxygenase in the maintenance of stemness and survival of
prostate cancer stem cells. Prostate cancer stem cells maintain stemness and tumorigenicity markers (Nanog, c-Myc, Sox2, CD44,
CD133, ALDH1, ABCG2), and survival/proliferation markers (survivin, cyclin D1, CDK4, Bcl-xl) (Green), but undergoes c-JNK-mediated
apoptosis when 5-lipoxygenase is inhibited (Red).
www.oncotarget.com
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The stem cell concept is enticing because of the
potential it can provide to more durable and widespread
cancer cures by identifying and attacking the tumor’s
most notorious cells. Evidence is slowly accumulating to
document that prostate cancer stem cells/tumor-initiating
cells are key drivers in initiation and progression of prostate
tumor. Therefore, successful therapy must eliminate these
cells, which is hampered by their high inherent resistance
to common therapeutic modalities. The discovery of cancer
stem cells has led to formulation of new strategies in future
therapy of prostate cancer. The so called “cancer normal
cells” can be eliminated by conventional therapies (surgery,
radiation, chemotherapy) relatively easily, though these are
rarely successful in attacking “cancer stem cells.” To be
successful, the new approach should therefore be to develop
therapeutic approaches to destroy these cancer stem cells.
Thus far, only a handful of studies have addressed the cancer
stem cell killing potential of standard apoptosis-inducing
therapies and the underlying molecular mechanisms of
apoptosis-resistance in these cells. Though our knowledge
of PCSCs and their microenvironment remains a relatively
new field, our current observations of PCSC’s critical
dependence upon 5-Lox activity for survival, as well as
for the maintenance of self-renewal markers, make this
regulatory mechanism ripe for developing experimental
agents for effective management of prostate cancer.
However, though it may be of high significance for
development of durable prostate cancer therapy, whether
5-Lox activity plays any role in the survival of prostate
cancer stem cells was never addressed before. This report
documents that inhibition of 5-Lox, triggers rapid and
wide-spread apoptosis in prostate cancer stem cells via
activation of c-Jun N-terminal Kinase, and that this process
is associated with down-regulation of PKCε, but not Akt or
ERKs as we observed in regular prostate cancer cells [23–
26, 37]. Moreover, inhibition of 5-Lox induces dramatic loss
of stemness factors which are known to play important roles
in self-regeneration and pluripotency of cancer stem cells.
These findings indicate that 5-Lox activity may contribute
to the survival and apoptosis-resistance of prostate cancer
stem cells by metabolic conversion of arachidonic acid (an
omega-6 polyunsaturated fatty acid, plentiful in our diets)
and activation of PKCε, a transforming oncogene, and
suggest that targeting 5-Lox with suitable agents may yield
clues about effective, long-lasting therapy of prostate cancer
and prevention of prostate cancer recurrence.

provided by the supplier. CD133+ human cord blood
stem cells were isolated by Dr. N. Varma from fresh
cord blood (provided by the Henry Ford Hospital) using
antibody-coated magnetic beads (Miltenyi Biotech, San
Diego, CA, USA). Human foreskin fibroblasts (HFF)
and DU-145 prostate cancer cells were purchased from
American Type Culture Collection (Manassas, VA, USA)
and were grown in RPMI or DMEM medium 1640
(Invitrogen, Carlsbad, CA, USA). All the media were
supplemented with 10% FBS and antibiotics. Antibodies
against Nanog, c-Myc and survivin were purchased
from R and D Systems (Minneapolis, MN, USA), and
antibodies against, Sox2, CD44, CD133, ABCG-2,
cyclin D1, CDK4, and Bcl-xl were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Polyclonal
antibodies against Akt, phospho-Akt (Ser473), phosphoERK1/2 (Thr202/Y204), phospho-JNK (Thr183/Y185), and
phospho-Stat3 (Ser727), were purchased from Cell
Signaling Technology (Danvers, MA, USA). Monoclonal
anti-5-Lox antibody was purchased from BD Biosciences
(Lexington, KY, USA). Anti-beta-actin antibody, ibuprofen
and cisplatin were purchased from Sigma Chemical CO
(St. Louis, MO, USA). MK591 was obtained as a generous
gift from Dr. Robert N. Young (Merck-Frosst Centre for
Therapeutic Research, Quebec, Canada).

Cell viability assay
Cell viability was measured by MTS/PES One
Solution Cell Titer Assay (Promega Corp, Madison, WI,
USA) as described before [23–26].

Microscopy
Cells (~3 × 105) were plated in complete growth
medium supplemented with 10% FBS overnight onto
60mm diameter tissue culture plates (Falcon) and allowed
to grow for 48 hours. On the day of experiment, the spent
culture medium was replaced with 2ml fresh RPMI medium
and the cells were treated with inhibitors. Control cells were
treated with solvent only (0.2% DMSO). Photographs were
taken with a Nikon digital camera attached to a LEICA
fluorescence microscope at ×400. Image acquisition and
data processing were done with a Dell computer attached
to the microscope using Q-Capture 7 software.

Annexin-V binding

MATERIALS AND METHODS

Cells (~3 × 105) were plated in complete medium and
allowed to grow for 48 hours. On the day of experiment,
the spent culture medium was replaced with fresh 2ml
medium and the cells were treated with MK591 or
ibuprofen for 24 hours at 37°C. Then the cells were treated
with FITC-labeled annexin-V and propidium-iodide for 15
minutes in the dark using an Annexin V-Binding Detection

Cell culture and reagents
Well-characterized human tumor-derived prostate
cancer stem cells (CD133+, CD44+, ALDH1+, ABCG2+,
Nanog+, c-Myc+) were purchased from Celprogen,
Torrance, CA, USA [7] and were cultured in medium
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Soft-agar colony formation assay

Kit following a protocol supplied by the manufacturer
(BD Biosciences). After washing, cells were photographed
using a Nikon digital camera attached to a LEICA
fluorescence-microscope at 20×. Image acquisition and
data processing were done with a Dell computer attached
to the microscope using Q-Capture 7 software.

Colony formation assays were performed in six
well plates by placing ~5,000 Cells in 0.5 ml of 0.3%
soft-agar on top of a 2 ml base layer of 0.6% agar. Plates
were allowed to settle and then the wells were covered
with 2 ml fresh medium containing 10% FBS with or
without inhibitors. Plates were incubated at 37°C in the
CO2 incubator for a maximum period of three weeks. Cell
growth medium and inhibitors were exchanged every
fourth day. At the end of incubation, cells were stained
with 0.25% crystal violet and colonies were counted under
a Leica microscope at ×150.

Western blot
Cells (~3 × 105) were plated in 60mm diameter
tissue culture plates and allowed to grow for 48 hours.
The old medium was then replaced with 2ml fresh medium
and the cells were treated with inhibitors. After treatment,
cells were harvested, washed, and lysed in lysis buffer (50
mM HEPES, pH 7.4, 150mM NaCl, 1mM EDTA, 1 mM
orthovanadate, 10mM sodium pyrophosphate, 10 mM
sodium fluoride, 1% NP-40, and a cocktail of protease
inhibitors). Proteins were separated by 12% SDS–PAGE
and transferred to nitrocellulose membranes. Membranes
were blocked with 5% nonfat-milk solution and then
blotted with appropriate primary antibodies followed
by peroxidase-labeled secondary antibody. Bands were
visualized by enhanced chemiluminescence (ECL)
detection kit from Pierce Biotech (Rockford, IL, USA)
and analyzed with a densitometer using Kodak imaging
software. Unless otherwise mentioned, protein blots were
analyzed in three independent experiments.

Measurement of DNA degradation
Apoptosis was quantitatively measured by
detecting degradation of nuclear DNA to nucleosomal
fragments by sandwich-ELISA. Cells (~3 × 105) were
plated in 60 mm dishes and allowed to grow for 48 hours.
Cells were then treated either with the experimental
agents or the solvent vehicle for varying periods of
time up to 24 hours. At the end of incubation periods,
cells were lysed and the degradation of chromatin
DNA to nucleosomal fragments was measured by Cell
Death Detection ELISAplus as described before [25, 26],
following instructions supplied by the manufacturer
(Roche, Indianapolis, IN, USA).

Luciferase assay

CONCLUSIONS

PCS cells were transfected with lentiviral Nanogluciferase constructs (> 90% cells transfected), expanded,
and re-plated in 96 well culture plates in triplicates. Cells
were then treated with MK591 or solvent only, and the
luciferase activity was measured by a Luciferase Assay
Kit from Promega Corporation (Madison, WI, USA)
as we reported recently [25, 26]. Ibu (ibuprofen, a
cyclooxygenase inhibitor) was used as negative control in
parallel assays under the same culture conditions.

Our findings revealed a new mechanism in the
regulation of stemness and survival of prostate cancer stem
cells, which suggests that by blocking 5-lipoxygenase
activity with suitable agents we can effectively eliminate
prostate cancer’s most-resistant cells for development of a
curative therapy of clinical prostate cancer and to prevent
prostate cancer recurrence.

Abbreviations

Invasion assay

PCSC, prostate cancer stem cells; CBSC, cord
blood stem cells; PKCε, protein kinase C-epsilon);
5-lox, 5-lipoxygenase; 5-oxoETE, 5-oxoeicosatetraenoic
acid; PARP, poly-ADP ribose polymerase; ELISA,
enzyme-linked immunosorbent assay; FITC, fluorescein
isothiocyanate.

Invasion chambers (BD Biosciences) were soaked
with 50 μl DMEM medium for 30 minutes at room
temperature in cell culture hood. Then, a 50 μl single cell
suspension of ~40,000 PCSCs in DMEM was gently placed
on top of the matrigel with or without drugs. These chambers
were then placed in twenty four well cell culture plates (one
in each well) containing 500 μl of DMEM medium plus 2%
serum as attractant. The chambers were incubated overnight
in the incubator at 37°C. On the next day, matrigels inside
the chambers were carefully scraped out and the membranes
were fixed in methanol, stained with crystal violet, mounted
on glass slides and counted under microscope.
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